fda import alert semaglutide tirzepatide green list Food and Drug Administration Issues GLP-1 API FDA Demurs on GLP-1 Compounding

Serving Size: One Vegetarian Capsule

This binding triggers several powerful effects: Slowing stomach emptying, making you feel fuller longer Reducing appetite signals in your brains hunger centre Improving insulin release and blood sugar control Blocking glucagon (a hormone that raises blood sugar) These medications work by mimicking the GLP-1 hormone, which is naturally produced by the gut after eating

Consistent with the reductions in BRI, cardiovascular disease risk factors improved in Surmount 1, although sex differences could not be ascertained as male and female observations were pooled in the pivotal publication [2]

The healthcare provider will evaluate the patients overall health, treatment goals, and potential risks to ensure that semaglutide is appropriate for their situation

Semaglutide also has evidence for cardiovascular risk reduction, while Wegovy was approved in 2025 for MASH with moderate-to-advanced liver fibrosis